High-Flow Nasal Cannula for severe COVID-19, a multicentre prospective cohort study
- Conditions
- <p>COVID-19</p>
- Registration Number
- NL-OMON19993
- Lead Sponsor
- o sponsors
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 600
The population included will be hospitalized patients with confirmed COVID-19, = 18 years old with isolated severe hypoxic respiratory failure defined as: SpO2 < 92% and/or BF>30/min despite treatment with at least 6 L/min oxygen therapy on nasal cannula. These patients may be included at the pulmonary departments delivering COVID-19 care, intensive care units or directly on the Emergency department. SARS-CoV-2 negative patients (nasopharyngeal PCR) will be excluded for this analysis, retrospectively.
Inclusion criteria
In order to be eligible to participate in this study, a subject must meet all of the following inclusion criteria:
? Age = 18 years
? Admitted to the hospital
? Suspect of COVID-19 or nasopharyngeal swab PCR confirmed COVID-19
? SpO2 < 92% and/ or breathing frequency >30/min despite at least 6L O2/min on nasal cannula.
A potential subject who meets any of the following criteria will be excluded from participation in this study:
? Reasons for direct intubation, as per local standard of clinical care.
? Patient does not accept treatment with HFNC
? Anatomic abnormalities (recent surgery of the face, nose, or airway) that preclude an appropriate-fitting nasal cannula
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary study endpoint is HFNC failure. HFNC failure is defined as: ? Patients without a DNI policy: Intubation. or ? Patients with DNI policy: Persistent hypoxemia, defined as SpO2 < 90% despite a maximum FiO2 (>90%) and flow (>50L/min) and/or death because of terminal respiratory failure.</p><br>
- Secondary Outcome Measures
Name Time Method